SAN FRANCISCO, October 26, 2007 – MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the company’s growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants.

“MedImmune is pleased to present data that provide key insights into how we can optimize the fight against RSV,” said Jessie R. Groothuis, M.D., vice president, medical and scientific affairs, infectious disease. “Cost-effectiveness data help insurers, governments, and families understand the benefits of RSV prophylaxis and the potential impact of not taking preventive measures. Surveillance data help us understand local variants in RSV outbreaks, which can inform and improve RSV prevention guidelines.”

MedImmune abstracts to be presented at AAP include:

• Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis with Palivizumab Among Preterm Infants After Valuing a Reduction in Persistent Wheezing (Poster #P14) – Mark J. Polak, M.D., Saturday, October 27th, 2007 from 12:15 – 1:00 p.m.

  BACKGROUND: Recent trials have suggested that Synagis® (palivizumab), a monoclonal antibody (MAb) that is the standard of care in RSV prevention, reduced the incidence of persistent wheezing in studied populations. Researchers conducted a cost-effectiveness analysis of prophylaxis with Synagis compared with no prophylaxis among preterm infants less than 32 weeks and between 32 and 35 weeks gestation, factoring in the quality of life associated with a reduction in persistent wheezing.

• A Nationwide Hospital RSV Surveillance Program: Interim Assessment of the 2006-2007 RSV Season (Poster #P25) – Marnie L. Boron, PharmD, Saturday, October 27th, 2007 from 12:15 – 1:00 p.m.

  BACKGROUND: Due to limited uniformity in RSV testing and local surveillance reporting, nationwide RSV prevention programs are not optimal. A nationwide surveillance program was initiated to track and report RSV activity at the local level in a timely manner. This abstract includes an interim report of the data collected to date.

• Regional Respiratory Syncytial Virus Surveillance Data for Georgia and Implications for Prophylactic Administration of Palivizumab (Poster #P32) – Mark Eggleston, PharmD, MBA, Saturday, October 27th, 2007 from 12:15 – 1:00 p.m.

  BACKGROUND: The Georgia Division of Public Health initiated an RSV surveillance program in mid-2000 to monitor RSV activity within four regions of the state. This study aimed to identify the onset, duration, and peak month of the RSV season in each of the four regions and evaluate whether national guidelines for RSV prophylaxis with Synagis are sufficient or whether recommendations should be based on local RSV virology data.